tbuckley/cabot-search huggingface dataset:
351P Impact of time to initiation post-operative adjuvant chemo-radiation in glioblastoma multiform: A systematic review
Authors: S. Sudibio, J. Anton, H. Handoko, E. Nuryadi, T.B.M. Permata, H. Kodrat, E. Susanto, H. Sofyan, R.A. Aman, S. Gondhowiardjo
Journal: Annals of Oncology (2021)
Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC
Authors: Zhengbo Song, Shifeng Lian, Silvia Mak, Maggie Zi-Ying Chow, Chunwei Xu, Wenxian Wang, Hoi Yee Keung, Chenyu Lu, Firaol Tamiru Kebede, Yanqiu Gao, Wah Cheuk, William Chi Shing Cho, Mengsu Yang, Zongli Zheng
Journal: Journal of Thoracic Oncology (2021)

Gene fusion variants in ALK-rearranged NSCLC may predict patient outcomes, but previous results have been inconclusive. Fusion isoforms coexisting in the same tumor may affect the efficacy of targeted therapy, but they have not been investigated.Patients with ALK-rearranged NSCLC who received crizotinib treatments were recruited. Precrizotinib tumor tissues were analyzed by the anchored multiplex polymerase chain reaction for targeted RNA sequencing. Kaplan-Meier and Cox regression were used to compare overall and progression-free survivals.Of the 51 studied subjects, EML4-ALK variant types v1, v2, v3, and others were detected in 23 (45.1%), five (9.8%), 19 (37.3%), and four patients (7.8%), respectively. Multiple EML4-ALK RNA isoforms were detected in 24 tumors (47.1%), and single isoform in 27 (52.9%). Most of the v3 tumors (16 of 19) harbored both v3a and v3b RNA isoforms. Multiple isoforms were also detected in eight non-v3 tumors (33.3% of all 24 multiple isoforms; five v1, two v5', and one v2). Compared with patients with single isoform, those with multiple isoforms had worse progression-free (hazard ratio and 95% confidence interval: 2.45 [1.06-5.69]) and overall (hazard ratio [95% confidence interval]: 3.74 [1.26-11.13]) survivals after adjusting for potential confounders including variant type. Using the patient-derived H2228 cells known to express v3a and v3b, our single-cell polymerase chain reaction detected either v3a or v3b in most single cells. Treatment of H2228 cells by three ALK inhibitors revealed increased ratios of v3a-to-v3b expression over time.Intratumoral EML4-ALK isoforms may predict the efficacy of targeted therapy in ALK-rearranged NSCLC. Temporal changes of intratumoral fusion isoforms may result from differential selection pressures that a drug might have on one isoform over another. Larger studies on fusion heterogeneity using RNA sequencing are warranted.
675P Changes in treatment patterns and survival in renal cell carcinoma (RCC) patients in Norway: A nationwide registry study for 1995-2018
Authors: K. Puco, C. Notland, R. Szulkin, C. Jonasson, C. Beisland, T. Børge Johannesen, O. Solli, J. Oldenburg, D. Heinrich
Journal: Annals of Oncology (2021)
676P CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
Authors: G. De Velasco, T. Alonso-Gordoa, J.F. Rodríguez-Moreno, I. Duran, A. Carretero-González, M. Martin-Soberon, J.L. Gutiérrez Baños, F. Guerrero-Ramos, M. Dueñas, D. Castellano Gauna
Journal: Annals of Oncology (2021)
257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Authors: S. Loibl, D. Loirat, S.M. Tolaney, K. Punie, M. Oliveira, H.S. Rugo, A. Bardia, S.A. Hurvitz, A. Brufsky, K. Kalinsky, J. Cortés, J. O'Shaughnessy, V.C. Dieras, L.A. Carey, L. Gianni, M. Gharaibeh, L. Moore, L. Shi, M. Piccart
Journal: Annals of Oncology (2021)
New-generation endocytoscopy for optical characterization of elevated-type early gastric cancer
Authors: Wen-Lun Wang, Hsiu-Po Wang, Ming-Lun Han, Ching-Tai Lee
Journal: Endoscopy (2021)

Narrow-band imaging with magnification is a tool often used to predict the histology of early depressed-type gastric cancer on the basis of the observation of the vascular and surface structure [1]. However, it can be relatively difficult to characterize elevated-type lesions because the alert signs, such as microvascular pattern or demarcation line, are sometimes obscure [2]. New-generation endocytoscopy (single lens, continuous zoom) enables in vivo ultrahigh magnification (× 520) for direct visualization at the cellular level and allows a precise pathological prediction of gastrointestinal neoplasia [3]. Herein, we report two patients with gastric elevated lesions that were characterized accurately by endocytoscopy ([Video 1]).
392P Integrating fragmentomic features for non-invasive early detection of colorectal advanced adenoma and adenocarcinoma
Authors: J. Peng, W. Tang, H. Bao, S. Mo, X. Ma, R. Liu, X. Chen, S. Wu, Y. Li, L. Zhang, F. Liu, X. Wu, Y. Shao, S. Cai
Journal: Annals of Oncology (2021)
Abstract 3213: Clinical Significance of Circulating Concentration of High-Mobility Group Box 1 (HMGB1) in Patients with Acute Coronary Syndrome
Authors: Shigeru Matsui, Junnichi Ishii, Masanori Okumura, Shino Kan, Tadashi Nakano, Hiroyuki Naruse, Yoshihisa Mori, Masanori Nomura, Hitoshi Hishida, Yukio Ozaki
Journal: Circulation (2007)
Human glioma cancer stem cells promote tumor invasion through gelatinases- MMP-2 and MMP-9
Authors: Hongyu Zhao, Hongwei Yu, Yunjie Wang, Yunhui Liu
Journal: Cancer Research (2008)

1143  Malignant gliomas are the most common and most aggressive brain tumors because of their highly invasive growth. Matrix metalloproteinases (MMPs), which degrade protein components of the extra-cellular matrix and basement membrane, particularly gelatinases (MMP-2 and -9) seem to be largely involved in cancer invasiveness. Some evidence has suggested that a small group of cells within glioma mass possesses similar features with neural stem cells (NSCs). This subpopulation isolated from human glioma cells has been identified as Cancer Stem Cells (CSCs), may play a key role in tumor initiation and maintenance. The invasion property and geletinases gene expression of CSCs, however, are still unknown. In this study, spheres were isolated from three primary cultured cell lines established from glioblastoma multiforme (GBM) patients and tumor cells were identified as two different subpopulations _ glioma CSCs and non-CSCs. By three-dimensional cell invasion system, we determined that glioma CSCs presented markedly increased capability of invasiveness compared with non-CSCs in three GBM cell lines in vitro. CSCs derived from GBM cell lines formed tumors after implantation, which are characterized by widespread invasiveness, angiogenesis and proliferation, but very few tumors were generated in mouse brains implanted with non-CSCs. We also examined and compared the expression levels of gelatinases between two glioma subpopulations in vitro, and in mouse brains implanted with CSCs in vivo, respectively, through real-time RT-PCR, western blot assay and immunohistochemical staining. Glioma CSCs secreted significantly elevated gelatinase-A (MMP-2), but not gelatinase-B (MMP-9) compared to non-CSCs subpopulation in vitro. The expression levels of both MMP-2 and MMP-9 were strikingly increased in mouse brain tumor tissues derived from glioma CSCs, but few expression of MMP-9 was detected in adjacent normal mouse brain tissues. Furthermore, higher growth rate of MMP-9 expression level along with the time after implantation was detected than that of MMP-2 in tumor tissues. Our study for the first time provided evidence that glioma CSCs may enhance tumor invasiveness through gelatinases, and MMP-2 and -9 displayed distinguishable effects under different circumstances. Targeting gelatinases, especially MMP-9, specifically on glioma CSCs may provide a new insight and method for patient therapy by inhibiting glioma invasiveness.
Aberrant activation of m6A demethylase FTO renders HIF2α <sup>low/−</sup> clear cell renal cell carcinoma sensitive to BRD9 inhibitors
Authors: ChuanJie Zhang, Lu Chen, WeiJuan Lou, JunHui Su, JingYi Huang, Ao Liu, Yang Xu, HongChao He, Yi Gao, DanFeng Xu, QingQuan Li
Journal: Science Translational Medicine (2021)

Hypoxia-inducible factor 2α (HIF2α) antagonists are effective against clear cell renal cell carcinomas (ccRCCs) that highly express HIF2α. To identify potential drug targets in HIF2α low/− ccRCC, we constructed an epigenetic-focused single-guide RNA library and performed an in vivo CRISPR-Cas9 knockout screen in BALB/c nude mice transplanted with 786-O (HIF2α high ) or Caki-2 (HIF2α low/− ) cells. We found that the m6A demethylase fat mass and obesity-associated ( FTO ) gene was indispensable to the growth of HIF2α low/− but not HIF2α high ccRCC. Activation of FTO in HIF2α low/− ccRCC was caused by an increased intracellular α-ketoglutarate–to-succinate ratio and stabilized bromodomain-containing protein 9 ( BRD9 ) messenger RNA via m6A demethylation. RNA sequencing and chromatin immunoprecipitation sequencing profiling further revealed that SRY-box transcription factor 17 (SOX17) recruited BRD9 to de novo super enhancers associated with genes that feature prominently in ccRCC pathogenesis, including CCND1 , VEGFR2 , CDC20 , SRC , and MAPK6 . BRD9 knockdown or the BRD9-selective antagonist I-BRD9 suppressed the growth of HIF2α low/− but not HIF2α high ccRCC cells in vitro. In BALB/c nude mice bearing HIF2α low/− ccRCC cell line–derived xenografts and patient-derived tumor xenografts, I-BRD9 administration effectively inhibited tumor growth and prolonged the survival of tumor-bearing mice with greater efficacy than sunitinib. Together, these findings indicate that BRD9 is a druggable target for treating HIF2α low/− ccRCC.
Early sample tagging and pooling enables simultaneous SARS-CoV-2 detection and variant sequencing
Authors: Alon Chappleboim, Daphna Joseph-Strauss, Ayelet Rahat, Israa Sharkia, Miriam Adam, Daniel Kitsberg, Gavriel Fialkoff, Matan Lotem, Omer Gershon, Anna-Kristina Schmidtner, Esther Oiknine-Djian, Agnes Klochendler, Ronen Sadeh, Yuval Dor, Dana Wolf, Naomi Habib, Nir Friedman
Journal: Science Translational Medicine (2021)

A sequencing-based detection and genotyping assay for SARS-CoV-2 is based on early sample pooling using barcoded oligo hybridization.
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199
Authors: J.N. Graff, S. Tagawa, C. Hoimes, W. Gerritsen, U.N. Vaishampayan, T. Elliott, C. Hwang, A.J. Ten Tije, A.G. Omlin, R.S. McDermott, R. De Wit, P. Qiu, C. Poehlein, J. Kim, L. Suttner, R. Cristescu, M.J. Marton, C. Schloss, J.S. de Bono, E.S. Antonarakis
Journal: Annals of Oncology (2021)
345MO Treatment associated changes in the inflammatory microenvironment composition of brain metastases
Authors: A. Steindl, K. Feldmann, T. Hatziioannou, M. Kleinberger, K. Dieckmann, G. Widhalm, B. Gatterbauer, J.A. Hainfellner, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2021)
Autoimmune Hemolytic Anemias
Authors: Sigbjørn Berentsen, Wilma Barcellini
Journal: New England Journal of Medicine (2021)

Hemolytic anemias, which are rare, are often caused by autoimmune destruction of red cells. The hemolysis can be intravascular or extravascular. In general, IgG mediates warm antibody–induced hemolysis, and IgM cold antibody–induced hemolysis. Immunosuppression is the main treatment.
HIV-specific CAR T cells return to the clinic
Authors: Christopher W. Peterson
Journal: Journal of Clinical Investigation (2021)

Over the past decade, chimeric antigen receptor (CAR) T cells have emerged as the prototype gene therapy for B cell leukemias. These so-called living drugs are derived from a patient's own cells, reprogrammed to recognize and destroy cancer cells, and then reintroduced into the body. The huge success of this therapy for cancer is rooted in pioneering clinical and preclinical studies, established more than three decades ago, focused on persistent HIV-1 infection. In this issue of the JCI, Bingfeng Liu et al. revisit HIV-specific CAR T cells in an important clinical study that supports broader application of this groundbreaking therapy. Although curative endpoints were not achieved, these findings lay the foundation for augmented approaches applying combinatorial technologies including antigen supplementation.
1456P Impact of early palliative care in quality at the end of life in small cell lung cancer patients
Authors: N. Jiménez-García, L. Ronco-Dumas, F. Rivas-Ruiz, R. Quirós-López, C. Flores-Guardabrazo, C.M.M. Bravo, Y. Jamal-Ismail Ortiz, E. Pérez-Ruiz, V. Navarro, M.I. Carrasco-Zafra, R. Gómez, J.C. Domínguez, D. Pérez, I. Zarcos, M. Robles, A. Galeote, P. Cantizani, C. Quero, A. Rueda Dominguez, R. Villatoro
Journal: Annals of Oncology (2021)
1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
Authors: Q. Chu, K. Parikh, L. Paz-Ares, A. Navarro, B. Markman, R. Sarmiento, G. Kollia, C. He, K. Sanghavi, H. Chang, B. Fischer, U. Guha, S. Tannenbaum-Dvir, K. Wu, Y. Liu, N. Ready
Journal: Annals of Oncology (2021)
Association of early-life factors with prematurity-associated lung disease: prospective cohort study
Authors: Kylie Hart, Michael Cousins, W. John Watkins, Sarah J. Kotecha, A. John Henderson, Sailesh Kotecha
Journal: European Respiratory Journal (2021)

Background Although bronchopulmonary dysplasia (BPD) is associated with lung function deficits in childhood, many who develop BPD have normal lung function in childhood and many without BPD, including those born at 33–34 weeks of gestation, have lung dysfunction in childhood. Since the predictability of BPD for future lung deficits is increasingly doubted, we prospectively recruited preterm-born children to identify early-life factors associated with lung function deficits after preterm birth. Methods From 767 children aged 7–12 years who had their respiratory symptoms assessed, and had spirometry before and after a bronchodilator in our Respiratory Health Outcomes in Neonates (RHiNO) study, 739 (544 preterm-born at ≤34 weeks of gestation and 195 term-born) had satisfactory lung function. Data were analysed using multivariable logistic regression and mediation. Results When preterm-born children were classified according to their lung function, low lung function (prematurity-associated lung disease (PLD)) was associated with BPD, gestation and intra-uterine growth restriction (IUGR) on univariable logistic regression analyses. However, on multivariable logistic regression analyses, gestation (β= –0.153, se 0.051; p=0.003) and IUGR (OR 1.783, 95% CI 1.06–3.00; p=0.029) remained significantly associated with later deficits of lung function, but BPD (OR 0.99, 95% CI 0.52–1.89; p=0.974) did not. Mediation analyses confirmed these results. Conclusions Although traditionally BPD has been associated with low lung function in later life, the data show that gestation and IUGR are significantly associated with PLD in childhood, but BPD is not. By identifying children with PLD, we can better understand the underlying mechanisms and develop optimal therapies.
1417P Prediction of the peritoneal recurrence by macroscopic diagnosis of the serosal invasion in gastric cancer: Supplementary analysis of JCOG0110 study
Authors: M. Terashima, T. Sano, J. Mizusawa, K. Uemura, M. Tokunaga, T. Omori, H. Cho, Y. Hasegawa, Y. Akiyama, H. Tsujitani, Y. Kawashima, Y. Kawachi, S.W. Lee, N. Boku, T. Yoshikawa, M. Sasako
Journal: Annals of Oncology (2021)
58P Intrahepatic cholangiocarcinoma (iCCA) hidden amongst the unknown: A retrospective analysis of cancer of unknown primary (CUP) cases from a tertiary cancer centre
Authors: A-M. Conway, G. Morris, S. Smith, P. Manoharan, C.L. Mitchell, A. Backen, P. Oliveira, R. Hubner, A. Lamarca, M.G. McNamara, J.W. Valle, N. Cook
Journal: Annals of Oncology (2021)
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
Authors: Elisa Baldelli, K Alex Hodge, Guido Bellezza, Neil J Shah, Guido Gambara, Angelo Sidoni, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Lance Liotta, Johann de Bono, Niven Mehra, Ruth Riisnaes, Antonella Ravaggi, Franco Odicino, Maria Isabella Sereni, Matthew Blackburn, Angela Zupa, Giuseppina Improta, Perry Demsko, Lucio Crino', Vienna Ludovini, Giuseppe Giaccone, Emanuel F Petricoin, Mariaelena Pierobon
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) agents are broadly used in first-line and second-line treatment across different tumor types. While immunohistochemistry-based assays are routinely used to assess PD-L1 expression, their clinical utility remains controversial due to the partial predictive value and lack of standardized cut-offs across antibody clones. Using a high throughput immunoassay, the reverse phase protein microarray (RPPA), coupled with a fluorescence-based detection system, this study compared the performance of six anti-PD-L1 antibody clones on 666 tumor samples. Methods PD-L1 expression was measured using five antibody clones (22C3, 28–8, CAL10, E1L3N and SP142) and the therapeutic antibody atezolizumab on 222 lung, 71 ovarian, 52 prostate and 267 breast cancers, and 54 metastatic lesions. To capture clinically relevant variables, our cohort included frozen and formalin-fixed paraffin-embedded samples, surgical specimens and core needle biopsies. Pure tumor epithelia were isolated using laser capture microdissection from 602 samples. Correlation coefficients were calculated to assess concordance between antibody clones. For two independent cohorts of patients with lung cancer treated with nivolumab, RPPA-based PD-L1 measurements were examined along with response to treatment. Results Median-center PD-L1 dynamic ranged from 0.01 to 39.37 across antibody clones. Correlation coefficients between the six antibody clones were heterogeneous (range: −0.48 to 0.95) and below 0.50 in 61% of the comparisons. In nivolumab-treated patients, RPPA-based measurement identified a subgroup of tumors, where low PD-L1 expression equated to lack of response. Conclusions Continuous RPPA-based measurements capture a broad dynamic range of PD-L1 expression in human specimens and heterogeneous concordance levels between antibody clones. This high throughput immunoassay can potentially identify subgroups of tumors in which low expression of PD-L1 equates to lack of response to treatment.
Targeted Temperature Management after Cardiac Arrest
Authors: Dalane Kitzman, Amy Pastva, P Robert, J Mentz
Journal: New England Journal of Medicine (2021)

ventions are primarily due to improved skeletal muscle function. 3 We agree with Brunner regarding heterogeneity of the patients with heart failure in our trial.Notably, patients with preserved ejection fraction and those with reduced ejection fraction were included in the trial.We recently reported that among these two phenotypes, the participants with heart failure with preserved ejection fraction had significantly worse physical dysfunction and frailty at baseline and appeared to receive much greater benefit from the intervention, including benefit in terms of improved physical functioning and quality of life and lower rates of frailty, rehospitalization, and death. 4 Although the outcomes in our trial are clinically meaningful, we agree that a larger trial, adequately powered for clinical events and safety, will be needed to effect change in clinical practice and reimbursement.Ideally, such a trial would focus on patients with heart failure with preserved ejection fraction, given their worse baseline status, greater response to the intervention, and limited treatment options as compared with those with heart failure with reduced ejection fraction.
872P Association between event-free (EFS) and overall survival (OS) in newly diagnosed patients (pts) with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) ineligible for surgery
Authors: C.M. Black, S. Keeping, D. Chirovsky, K. Ramakrishnan, A. Mojebi, N. Upadhyay, D. Ayers
Journal: Annals of Oncology (2021)
422P The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: A summary analysis of a multicenter, phase II trial
Authors: X. Qu, Y. Liu, Z. Teng, Y. Zhang, D.Z. Zheng, L. Man, Z. Wang, Y. Wang, J. Zhang, H. Zhang, J. Liu, H. Chen, W.J. Xiao, Y. Jiang, J. Zhang, S. Liu, C. Wang
Journal: Annals of Oncology (2021)
Helen Salisbury: The time is now
Authors: Helen Salisbury
Journal: BMJ (2021)

Whenever I hear discussions about patients being too quick to call a doctor, and how their failure to self-manage is adding to NHS workloads, I’m reminded of patients who didn’t call until it was too late. We’ve all met people like this, who found reasons not to seek help and then presented with end stage cancer. The reasons they give themselves for delaying so long are many and varied, and reluctance to bother the doctor is often among them.

There is also fear, both of the diagnosis and of the treatment to follow: having …
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Authors: Daniel P. Regan, Lyndah Chow, Sunetra Das, Laurel Haines, Eric Palmer, Jade N. Kurihara, Jonathan W. Coy, Alissa Mathias, Douglas H. Thamm, Daniel L. Gustafson, Steven W. Dow
Journal: Clinical Cancer Research (2021)

Abstract Purpose: There is increasing recognition that progress in immuno-oncology could be accelerated by evaluating immune-based therapies in dogs with spontaneous cancers. Osteosarcoma (OS) is one tumor for which limited clinical benefit has been observed with the use of immune checkpoint inhibitors. We previously reported the angiotensin receptor blocker losartan suppressed metastasis in preclinical mouse models through blockade of CCL2–CCR2 monocyte recruitment. Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmacodynamic endpoints, and assess its antitumor activity, in combination with the kinase inhibitor toceranib. Patients and Methods: CCL2 expression, monocyte infiltration, and monocyte recruitment by human and canine OS tumors and cell lines were assessed by gene expression, ELISA, and transwell migration assays. Safety and efficacy of losartan-toceranib therapy were evaluated in 28 dogs with lung metastatic OS. Losartan PK and monocyte PD responses were assessed in three dose cohorts of dogs by chemotaxis, plasma CCL2, and multiplex cytokine assays, and RNA-seq of losartan-treated human peripheral blood mononuclear cells. Results: Human and canine OS cells secrete CCL2 and elicit monocyte migration, which is inhibited by losartan. Losartan PK/PD studies in dogs revealed that a 10-fold-higher dose than typical antihypertensive dosing was required for blockade of monocyte migration. Treatment with high-dose losartan and toceranib was well-tolerated and induced a clinical benefit rate of 50% in dogs with lung metastases. Conclusions: Losartan inhibits the CCL2–CCR2 axis, and in combination with toceranib, exerts significant biological activity in dogs with metastatic osteosarcoma, supporting evaluation of this drug combination in patients with pediatric osteosarcoma. See related commentary by Weiss et al., p. 571
1115P Beyond classic hereditary neuroendocrine tumors (NET) syndromes
Authors: C. Castillo Manzano, P. Guillén, J.M. Brunet Vidal, C. Lazaro, J.C.C. Ruffinelli, C. Santos Vivas, F. Torrent, R. Lleuger, I. Garcia-Fructuoso, A. Teule
Journal: Annals of Oncology (2021)
1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
Authors: X. Tang, W-L. Qian, T. Pang, Y-L. Gong, Z-G. Yang
Journal: Annals of Oncology (2021)